AKT1 and acute myeloid leukemia: This is because approximately 50–70% of patients with AML demonstrated constitutive activation of the SHIP-1-regulated P13K/Akt pathway, and approximately 3% displayed a missense mutation in INPP5D (Täger et al., 2017).